Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Aurinia Pharmaceuticals Inc. Is Surging Today

By Cory Renauer – May 14, 2018 at 12:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A planned expansion of its lead program has investors fired up.

What happened

Shares of Aurinia Pharmaceuticals Inc. (AUPH -3.17%), a clinical-stage biotech, are on the rise following the company's first-quarter earnings report. Plans to expand voclosporin, the company's lupus candidate, to a much larger indication inspired investors to push the shares 10.2% higher as of 1:03 p.m. Monday.

So what 

A pivotal trial for the treatment of lupus nephritis started a year ago, and the company's on track to send its first application to the FDA in the first half of 2020. Investors perked up today because it looks like they could have a couple of new catalysts to look forward to in the meantime. 

Man drawing an upward sloping chart.

Image source: Getty Images.

During its first-quarter report, Aurinia announced plans to begin a study for an extremely rare kidney disorder, plus plans to develop voclosporin drops to treat dry eye syndrome. It seems odd that a drug that appears to limit kidney damage also has a shot as a treatment for an eye condition that affects more than 20 million Americans, but we could find out soon. Merck & Co.'s Animal Health unit licensed rights to develop voclosporin for dogs with dry eye, and Aurinia slated a head-to-head human study against Allergan's (AGN) Restasis for this June.

Now what

Aurinia finished March with a healthy $159.1 million cash balance, which management thinks will see it through the planned filing of voclosporin's lupus application in early 2020 despite the increased clinical trial activity. Success against Restasis could send the stock soaring before phase 3 lupus results are even ready.

Before you get too fired up about a possible expansion to the enormous dry eye indication, it's important to remember that voclosporin solution for dry eye has been on the back burner a long time. Lux Biosciences reported positive results from a phase 1 trial with healthy volunteers and five dry-eye patients all the way back in 2009.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aurinia Pharmaceuticals Inc. Stock Quote
Aurinia Pharmaceuticals Inc.
$7.03 (-3.17%) $0.23
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$86.78 (-0.83%) $0.73
Allergan plc Stock Quote
Allergan plc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.